|
|
|
LifeScienceHistory.com - Check us out on Instagram
Maryland Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MarylandLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
NovaDigm Therapeutics, Inc.
| | | Phone: | (701) 757-5161 | Fax: | (701) 335-7121 | Year Established: | 2005 | Main Contact: | Tuomas Holmberg, CBO | | Other Contacts: | John P. Hennessey, Jr., Ph.D., CSO Timothy Cooke, Ph.D., CEO
| | Company Description | NovaDigm is developing innovative immunotherapeutics and preventative vaccines to protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. NovaDigm’s lead development candidate, NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The Company’s founding scientists from the Los Angeles Biomedical Research Institute (LA BioMed) at Harbor-UCLA Medical Center are recognized leaders in the field of infectious disease and the emerging threat of “superbugs.” NovaDigm has received funding from Domain Associates and RusnanoMedInvest and collaborates with multiple government agencies. | |
|
|
|
|
|